Jason Lilly Net Worth

The estimated Net Worth of Jason Warren Lilly is at least $1.57 Millón dollars as of 13 October 2023. Jason Lilly owns over 351 units of Neogen stock worth over $407,846 and over the last 5 years he sold NEOG stock worth over $410,524. In addition, he makes $754,069 as Vice President - International Business at Neogen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jason Lilly NEOG stock SEC Form 4 insiders trading

Jason has made over 17 trades of the Neogen stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 351 units of NEOG stock worth $5,300 on 13 October 2023.

The largest trade he's ever made was exercising 16,001 units of Neogen stock on 16 November 2020 worth over $647,400. On average, Jason trades about 3,805 units every 61 days since 2019. As of 13 October 2023 he still owns at least 26,744 units of Neogen stock.

You can see the complete history of Jason Lilly stock trades at the bottom of the page.

Jason Lilly biography

Dr. Jason Warren Lilly serves as Vice President - International Business of the Company. He joined Neogen in June 2005 as Market Development Manager for Food Safety. In June 2009, he moved to the Corporate Development group. He was named Vice President of Corporate Development in December 2011, responsible for the identification and acquisition of new business opportunities for the Company. In January 2019, Dr. Lilly was named Vice President of International Business, responsible for Neogen’s operations outside of the U.S. and Canada. Prior to joining Neogen, he served in various technical sales and marketing roles at Invitrogen Corporation.

What is the salary of Jason Lilly?

As the Vice President - International Business of Neogen, the total compensation of Jason Lilly at Neogen is $754,069. There are 3 executives at Neogen getting paid more, with John Adent having the highest compensation of $2,123,450.

How old is Jason Lilly?

Jason Lilly is 46, he's been the Vice President - International Business of Neogen since 2019. There are 13 older and no younger executives at Neogen. The oldest executive at Neogen Corp. is G. Bruce Papesh, 73, who is the Independent Director.

What's Jason Lilly's mailing address?

Jason's mailing address filed with the SEC is Neogen, 620, Lesher Place, Oak Park, Lansing, Ingham County, Michigan, 48912, United States.

Insiders trading at Neogen

Over the last 24 years, insiders at Neogen have traded over $135,917,555 worth of Neogen stock and bought 195,554 units worth $4,379,833 . The most active insiders traders include James L Herbert, Jeffrey D Capello y Lon M Bohannon. On average, Neogen executives and independent directors trade stock every 11 days with the average trade being worth of $140,346. The most recent stock trade was executed by Ronald D Green on 29 August 2024, trading 4,446 units of NEOG stock currently worth $68,780.

What does Neogen do?

neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.

Complete history of Jason Lilly stock trades at Neogen

Neogen executives and stock owners

Neogen executives and other stock owners filed with the SEC include:

• John Adent,
  President, Chief Executive Officer, Director
• Steven Quinlan,
  Chief Financial Officer, Vice President, Secretary
• John Edward Adent,
  Pres, CEO & Director
• Jason Lilly,
  Vice President - International Business
• Jerome Hagedorn,
  Vice President - Food Safety operations
• Douglas E. Jones,
  VP & Chief Commercial Officer
• Steven J. Quinlan,
  VP & CFO
• James Borel,
  Lead Independent Chairman of the Board
• James Tobin,
  Independent Director
• Ronald Green,
  Independent Director
• William Boehm,
  Independent Director
• Darci Vetter,
  Independent Director
• G. Bruce Papesh,
  Independent Director
• Doug Jones,
  Chief Commercial Officer
• Amy M. Rocklin Ph.D.,
  VP, Gen. Counsel & Corp. Sec.
• Julie A. Mann,
  VP & Chief HR Officer
• Rod Poland,
  Director of Corp. Communications
• Amy Rocklin Ph.D.,
  VP & Gen. Counsel
• Sarah Demey,
  Admin. Mang.
• Bruce Papesh,
  Director
• A Charles Fischer,
  Director
• Richard E Jr Calk,
  President & COO
• Richard T Crowder,
  Director
• Jack C Parnell,
  Director
• Clayton K Yeutter,
  Director
• Thomas H Reed,
  Director
• Terri A Morrical,
  
• David H. Naemura,
  Chief Financial Officer
• Edward Bradley,
  V.P. Sales and Marketing
• Aashima Gupta,
  Director
• Jeffrey D Capello,
  Director
• Rex L Hamilton,
  Vice President
• Herbert D Doan,
  Director
• Gordon E Guyer,
  Director
• James L Herbert,
  Director
• Joseph M Madden,
  V.P. Scientific Affairs
• Richard R Current,
  Vice President & CFO
• Anthony E Maltese,
  VP Business Development
• Kenneth V Kodilla,
  Vice President
• Lon M Bohannon,
  COO
• Mark A Mozola,
  Vice President of R&D
• Leonard E Heller,
  Director
• Robert M Book,
  Director
• Stephen K. Snyder,
  Former Pres. and COO
• Paul S Satoh,
  V.P Research and Development
• Rafael A Rodriguez,
  Director
• Catherine E Woteki,
  Director
• Amy M Rocklin,
  Chief Legal Officer
• John Patrick Moylan,
  Chief Accounting Officer